Notícias e Atividades da Beacon Therapeutics

A Beacon Therapeutics pertence à Syncona.

Syncona é uma das ...

• FTSE 350;
• TOB Iconic 10,000.

Syncona é uma empresa listada sob o símbolo SYNC (GB).

Syncona tem presença direta em 3 países.

Syncona possui 11 subsidiárias incluindo Anaveon, Autolus Therapeutics e Beacon Therapeutics.

Eles estão dentro:

• Biotecnologia83%
• Holding8%
• Outro8%

Fusão, aquisição e financiamento envolvendo Syncona.

• Beacon Therapeutics acaba de anunciar uma arrecadação de fundos de 75 milhões de dólares. (publicado em 8 de janeiro de 2026).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Beacon Therapeutics

• Lance Baldo, Chief Executive Officer
• Dave Fellow, Non-Executive Chairman of the Board
• Dmitrij Hristodorov, Investor Director

Recentes movimentos de executivos em Beacon Therapeutics

• Ryan Robinson, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 13 de março de 2026).

Recentes movimentos de executivos em Syncona

• Norman Crighton ingressará na Companhia como Independent Non-Executive Director em 1 de jul. de 2026  (Notícia publicada em 17 de junho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Beacon Therapeutics.

Syncona possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Beacon Therapeutics

• Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) - Beacon Therapeutics
• Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa - Beacon Therapeutics
• Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - Beacon Therapeutics
• Subretinal Gene Therapy Drug AGTC-501 for XLinked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (HORIZON): 36-Month Interim Results - Beacon Therapeutics
• Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer - Beacon Therapeutics
• Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications - Beacon Therapeutics
• Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501 - Beacon Therapeutics
• Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies - Beacon Therapeutics
• Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production - Beacon Therapeutics
• Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Phase 2 SKYLINE Trial - Beacon Therapeutics
• View more press releases Close

Redes sociais sobre Beacon Therapeutics

• Beacon Therapeutics na Wikipedia, Google News e Yahoo Finance
• Beacon Therapeutics na LinkedIn, X (Twitter) e YouTube